We are live on ! Find out more
XBIO icon

Xenetic Biosciences

6 hedge funds and large institutions have $453K invested in Xenetic Biosciences in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.6% less ownership

Funds ownership: 9.99%7.38% (-2.6%)

9% less capital invested

Capital invested by funds: $497K → $453K (-$43.6K)

45% less funds holding

Funds holding: 116 (-5)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

Holders
6
Holders Change
-5
Holders Change %
-45.45%
% of All Funds
0.07%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
1
Reduced
2
Closed
6
Calls
Puts
Net Calls
Net Calls Change

XBIO Hedge Fund Activity: Q1 2026 in Review

6 of the 8,132 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q1 2026, worth a combined $453K — down 8.8% from $497K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of XBIO and 1 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Geode Capital Management, adding an estimated $19.4K. The largest seller was Renaissance Technologies, cutting an estimated $101K.

  • 6 institutional investors held Xenetic Biosciences (XBIO) as of Q1 2026, down from 11 in Q4 2025.
  • Funds reported $453K of Xenetic Biosciences stock for Q1 2026, down 8.8% quarter-over-quarter.
  • 1 fund opened new Xenetic Biosciences positions in Q1 2026 and 6 closed out, a net change of -5 holders.
  • The largest Xenetic Biosciences buyer in Q1 2026 was Geode Capital Management, an estimated $19.4K added.
  • The largest Xenetic Biosciences seller in Q1 2026 was Renaissance Technologies, an estimated $101K sold.

Based on aggregated 13F filings for Q1 2026.